MiR200-upregulated Vasohibin 2 promotes the malignant transformation of tumors by inducing epithelial-mesenchymal transition in hepatocellular carcinoma

Cell Communication and Signaling

Volumn 12, Issue 1, 2014, Pages

  Xue, Xiaofeng ^a,b   Zhang, Ye ^a   Zhi, Qiaoming ^b   Tu, Min ^a   Xu, Yue ^a   Sun, Jie ^a   Wei, Jishu ^a   Lu, Zipeng ^a   Miao, Yi ^a   Gao, Wentao ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Epithelial mesenchymal transition (EMT); miR 200a b c; Vasohibin 2

Indexed keywords

ANGIOGENIC FACTOR; CHEMOKINE RECEPTOR CXCR4; GELATINASE A; MICRORNA 200; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN BCL 2; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR ZEB1; TRANSCRIPTION FACTOR ZEB2; UNCLASSIFIED DRUG; UVOMORULIN; VASOHIBIN 2; VIMENTIN; ANGIOGENIC PROTEIN; MICRORNA; MIRN200 MICRORNA, HUMAN; VASH2 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ABCC1 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BCL 2 GENE; BINDING SITE; BIOINFORMATICS; CELL STRUCTURE; CONTROLLED STUDY; CXCR4 GENE; DISEASE ASSOCIATION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HEP3B CELL LINE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER CELL LINE; LIVER CELL CARCINOMA; MALE; MALIGNANT TRANSFORMATION; MMP2 GENE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN FUNCTION; PROTEIN PROCESSING; TUMOR INVASION; TUMOR VOLUME; UPREGULATION; VASH2 GENE; WESTERN BLOTTING; ANIMAL; CANCER STEM CELL; CARCINOGENESIS; LIVER TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANGIOGENIC PROTEINS; ANIMALS; APOPTOSIS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; LIVER NEOPLASMS; MALE; MICE, NUDE; MICRORNAS; NEOPLASTIC STEM CELLS;

EID: 84907920645     PISSN: None     EISSN: 1478811X     Source Type: Journal    
DOI: 10.1186/s12964-014-0062-x     Document Type: Article

References (33)

1. Estimating the world cancer burden: Globocan 2000. DM Parkin, F Bray, J Ferlay, P Pisani, Int J Cancer 2001 94 153 156 10.1002/ijc.1440 11668491
2. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. TW Leung, YZ Patt, WY Lau, SK Ho, SC Yu, AT Chan, TS Mok, W Yeo, CT Liew, NW Leung, AM Tang, PJ Johnson, Clin Cancer Res 1999 5 1676 1681 10430068
3. Angiogenesis: an organizing principle for drug discovery? J Folkman, Nat Rev Drug Discov 2007 6 273 286 10.1038/nrd2115 17396134
4. Sorafenib in advanced hepatocellular carcinoma. JM Llovet, S Ricci, V Mazzaferro, P Hilgard, E Gane, JF Blanc, AC de Oliveira, A Santoro, JL Raoul, A Forner, M Schwartz, C Porta, S Zeuzem, L Bolondi, TF Greten, PR Galle, JF Seitz, I Borbath, D Haussinger, T Giannaris, M Shan, M Moscovici, D Voliotis, J Bruix, N Engl J Med 2008 359 378 390 10.1056/NEJMoa0708857 18650514
5. Complex networks orchestrate epithelial-mesenchymal transitions. JP Thiery, JP Sleeman, Nat Rev Mol Cell Biol 2006 7 131 142 10.1038/nrm1835 16493418
6. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. S Grunert, M Jechlinger, H Beug, Nat Rev Mol Cell Biol 2003 4 657 665 10.1038/nrm1175 12923528
7. Epithelial-mesenchymal transition in hepatocellular carcinoma. F van Zijl, G Zulehner, M Petz, D Schneller, C Kornauth, M Hau, G Machat, M Grubinger, H Huber, W Mikulits, Future Oncol 2009 5 1169 1179 10.2217/fon.09.91 19852728
8. The role of the miR-200 family in epithelial-mesenchymal transition. PS Mongroo, AK Rustgi, Cancer Biol Ther 2010 10 219 222 10.4161/cbt.10.3.12548 20592490
9. The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. M Korpal, Y Kang, RNA Biol 2008 5 115 119 10.4161/rna.5.3.6558 19182522
10. The ZEB/miR-200 feedback loop-a motor of cellular plasticity in development and cancer? S Brabletz, T Brabletz, EMBO Rep 2010 11 670 677 10.1038/embor.2010.117 20706219
11. Roles of intrinsic angiogenesis inhibitor, vasohibin, in cervical carcinomas. K Yoshinaga, K Ito, T Moriya, S Nagase, T Takano, H Niikura, H Sasano, N Yaegashi, Y Sato, Cancer Sci 2011 102 446 451 10.1111/j.1349-7006.2010.01812.x 21175993
12. Isolation and characterization of vasohibin-2 as a homologue of VEGF-inducible endothelium-derived angiogenesis inhibitor vasohibin. T Shibuya, K Watanabe, H Yamashita, K Shimizu, H Miyashita, M Abe, T Moriya, H Ohta, H Sonoda, T Shimosegawa, K Tabayashi, Y Sato, Arterioscler Thromb Vasc Biol 2006 26 1051 1057 10.1161/01.ATV.0000216747.66660.26 16528006
13. Distinctive localization and opposed roles of vasohibin-1 and vasohibin-2 in the regulation of angiogenesis. H Kimura, H Miyashita, Y Suzuki, M Kobayashi, K Watanabe, H Sonoda, H Ohta, T Fujiwara, T Shimosegawa, Y Sato, Blood 2009 113 4810 4818 10.1182/blood-2008-07-170316 19204325
14. Vasohibin 2 is transcriptionally activated and promotes angiogenesis in hepatocellular carcinoma. X Xue, W Gao, B Sun, Y Xu, B Han, F Wang, Y Zhang, J Sun, J Wei, Z Lu, Y Zhu, Y Sato, Y Sekido, Y Miao, Y Kondo, Oncogene 2013 32 1724 1734 10.1038/onc.2012.177 22614011
15. Vasohibin-2 expressed in human serous ovarian adenocarcinoma accelerates tumor growth by promoting angiogenesis. Y Takahashi, T Koyanagi, Y Suzuki, Y Saga, N Kanomata, T Moriya, M Suzuki, Y Sato, Mol Cancer Res 2012 10 1135 1146 10.1158/1541-7786.MCR-12-0098-T 22826464
16. Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma. DJ Tang, SS Dong, NF Ma, D Xie, L Chen, L Fu, SH Lau, Y Li, XY Guan, Hepatology 2010 51 1255 1263 10.1002/hep.23451 20112425
17. The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. S Spaderna, O Schmalhofer, M Wahlbuhl, A Dimmler, K Bauer, A Sultan, F Hlubek, A Jung, D Strand, A Eger, T Kirchner, J Behrens, T Brabletz, Cancer Res 2008 68 537 544 10.1158/0008-5472.CAN-07-5682 18199550
18. Expression of the ZEB1 (deltaEF1) transcription factor in human: additional insights. EM Hurt, JN Saykally, BM Anose, KR Kalli, MM Sanders, Mol Cell Biochem 2008 318 89 99 10.1007/s11010-008-9860-z 18622689
19. ZEB/miR-200 feedback loop: at the crossroads of signal transduction in cancer. L Hill, G Browne, E Tulchinsky, Int J Cancer 2013 132 745 754 10.1002/ijc.27708 22753312
20. The transcription factor ZEB1 (deltaEF1) represses Plakophilin 3 during human cancer progression. K Aigner, L Descovich, M Mikula, A Sultan, B Dampier, S Bonne, F van Roy, W Mikulits, M Schreiber, T Brabletz, W Sommergruber, N Schweifer, A Wernitznig, H Beug, R Foisner, A Eger, FEBS Lett 2007 581 1617 1624 10.1016/j.febslet.2007.03.026 17391671
21. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. A Eger, K Aigner, S Sonderegger, B Dampier, S Oehler, M Schreiber, G Berx, A Cano, H Beug, R Foisner, Oncogene 2005 24 2375 2385 10.1038/sj.onc.1208429 15674322
22. Circulating tumor cells as a window on metastasis biology in lung cancer. JM Hou, M Krebs, T Ward, R Sloane, L Priest, A Hughes, G Clack, M Ranson, F Blackhall, C Dive, Am J Pathol 2011 178 989 996 10.1016/j.ajpath.2010.12.003 21356352
23. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. T Brabletz, A Jung, S Reu, M Porzner, F Hlubek, LA Kunz-Schughart, R Knuechel, T Kirchner, Proc Natl Acad Sci U S A 2001 98 10356 10361 10.1073/pnas.171610498 11526241
24. Development and characterization of gemcitabine-resistant pancreatic tumor cells. AN Shah, JM Summy, J Zhang, SI Park, NU Parikh, GE Gallick, Ann Surg Oncol 2007 14 3629 3637 10.1245/s10434-007-9583-5 17909916
25. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Z Wang, Y Li, D Kong, S Banerjee, A Ahmad, AS Azmi, S Ali, JL Abbruzzese, GE Gallick, FH Sarkar, Cancer Res 2009 69 2400 2407 10.1158/0008-5472.CAN-08-4312 19276344
26. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. AD Yang, F Fan, ER Camp, G van Buren, W Liu, R Somcio, MJ Gray, H Cheng, PM Hoff, LM Ellis, Clin Cancer Res 2006 12 4147 4153 10.1158/1078-0432.CCR-06-0038 16857785
27. The epithelial-mesenchymal transition generates cells with properties of stem cells. SA Mani, W Guo, MJ Liao, EN Eaton, A Ayyanan, AY Zhou, M Brooks, F Reinhard, CC Zhang, M Shipitsin, LL Campbell, K Polyak, C Brisken, J Yang, RA Weinberg, Cell 2008 133 704 715 10.1016/j.cell.2008.03.027 18485877
28. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. M Santisteban, JM Reiman, MK Asiedu, MD Behrens, A Nassar, KR Kalli, P Haluska, JN Ingle, LC Hartmann, MH Manjili, DC Radisky, S Ferrone, KL Knutson, Cancer Res 2009 69 2887 2895 10.1158/0008-5472.CAN-08-3343 19276366
29. Cancer stem cells: mirage or reality? PB Gupta, CL Chaffer, RA Weinberg, Nat Med 2009 15 1010 1012 10.1038/nm0909-1010 19734877
30. Epithelial-mesenchymal transitions and hepatocarcinogenesis. J Jou, AM Diehl, J Clin Invest 2010 120 1031 1034 10.1172/JCI42615 20335655
31. Epithelial-to-mesenchymal transition of murine liver tumor cells promotes invasion. W Ding, H You, H Dang, F LeBlanc, V Galicia, SC Lu, B Stiles, CB Rountree, Hepatology 2010 52 945 953 10.1002/hep.23748 20564331
32. Hedgehog signaling, epithelial-to-mesenchymal transition and miRNA (review). Y Katoh, M Katoh, Int J Mol Med 2008 22 271 275 18698484
33. Evaluation of tumor microvascular response to brivanib by dynamic contrast-enhanced 7-T MRI in an orthotopic xenograft model of hepatocellular carcinoma. KD Song, D Choi, JH Lee, GH Im, J Yang, JH Kim, WJ Lee, Am J Roentgenol 2014 202 559 566 10.2214/AJR.13.11042